SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society; 2008.
  • 2
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83: 584-594.
  • 3
    Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase 3 trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210-3218.
  • 4
    Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 5
    Delbaldo C, Michiels S, Rolland E, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev. 2007; 4: CD004569.
  • 6
    Smylie M, Mercier R, Aboulafia D, et al. Phase 3 study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2001; 20. Abstract 1226.
  • 7
    Bissett D, O'Byrne KJ, von Pawel J, et al. Phase 3 study of matrix metalloproteinase inhibitor prinomastat in non–small-cell lung cancer. J Clin Oncol. 2005; 23: 842-849.
  • 8
    Leighl N, Paz-Ares L, Douillard J-Y, et al. Randomized phase 3 study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: National Cancer Institute of Canada–Clinical Trials Group study BR. 18. J Clin Oncol. 2005; 23: 2831-2839.
  • 9
    Manegold C, Thatcher N, Benner RJ, Readett D, van Zandwijk N. Randomized phase 3 trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8017.
  • 10
    Hirsh V, Boyer M, Rossell R, Benner RJ, Readett D, Schiller JH. Randomized phase 3 trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8016.
  • 11
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase 3 trial—INTACT 1. J Clin Oncol. 2004; 22: 777-784.
  • 12
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase 3 trial—INTACT 2. J Clin Oncol. 2004; 22: 785-794.
  • 13
    Gatzemeier U, Pluzanska A, Szcesna A, et al. Phase 3 study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation trial. J Clin Oncol. 2007; 25: 1545-1552.
  • 14
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase 3 trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
  • 15
    Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase 3 trial comparing bexarotene (L1069–49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol. 2008; 26: 1886-1892.
  • 16
    Blumenschein GR Jr, Khuri FR, von Pawel J, et al. Phase 3 trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non–small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008; 26: 1879-1885.
  • 17
    Lynch TJ, Raju R, Lind M, et al. Randomized phase 3 trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report [abstract]. J Clin Oncol. 2003; 22( suppl). Abstract 2504 and slide presentation.
  • 18
    Paz-Ares L, Douillard J-Y, Koralewski P, et al. Phase 3 study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2006; 24: 1428-1434.
  • 19
    Bayer and Onyx provide update on phase 3 trial of Nexavar in patients with non-small cell lung cancer [news release]. Bayer Healthcare Pharmaceuticals, Onyx Pharmaceuticals: Montville, NJ; February 18, 2008.
  • 20
    AstraZeneca provides update on Recentin clinical development programme [press release]. Wilmington, DE: AstraZeneca; February 27, 2008.
  • 21
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumors. Eur Respir J. 2001; 18: 1059-1068.
  • 22
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase 3 study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
  • 23
    Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25: 561-570.
  • 24
    Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-13311.
  • 25
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
  • 26
    Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-144.
  • 27
    Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non–small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21. Clin Lung Cancer. 2006; 7: 389-394.
  • 28
    Hanna N, Lilenbaum R, Ansari R, et al. Phase 2 trial of cetuximab in patients with previously treated non–small-cell lung cancer. J Clin Oncol. 2006; 24: 5253-5258.
  • 29
    Rosell R, Robinet G, Szczesna A, et al. Randomized phase 2 study of cetuximab plus cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non–small-cell lung cancer. Ann Oncol. 2008; 19: 362-369.
  • 30
    Butts CA, Bodkin D, Middleman EL, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2007; 25( 18S): 5777-5784. Abstract 7539.
  • 31
    Buyse ME, Squifflet P, Laporte S, et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8019.
  • 32
    Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non–small-cell lung cancer. J Clin Oncol. 2003; 21: 2094-2100.
  • 33
    Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase 2 study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least 2 prior chemotherapy regimens: E2501 [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8014.
  • 34
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
  • 35
    Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL. J Clin Oncol. 2009; 27: 1227-1234.
  • 36
    Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase 3 study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 3 and presented slides.
  • 37
    Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase 3 study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer [abstract]. J Thor Oncol. 2007; 2( suppl 4). Abstract B3–03 and presented slides.
  • 38
    Reck M, von Pawel J, Zatloukal P, et al. First-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, nonsmall cell lung cancer: AVAiL (BO17704), a phase III randomised study [abstract]. J Thor Oncol. 2008; 3( suppl 4): S302.
  • 39
    Lynch TJ, Patel T, Dreisbach L, et al. Overall survival (OS) results from the phase III trial BMS099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC [abstract]. J Thor Oncol. 2008; 3( suppl. 4): S305.
  • 40
    Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2008.
  • 41
    Dansin E, Mezger J, Isla D, et al. Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer: MO19390 (SAiL) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8085.
  • 42
    Lynch TJ, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8077.
  • 43
    Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab in patients with brain metastases due to non-small cell lung cancer [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8043.
  • 44
    Griesinger F, Laskin JJ, Pavlakis N, on behalf of the MO19390 (SAiL) Study Group. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8049.
  • 45
    Kim ES, Herbst RS, Moon J, et al. S0536: SWOG phase II trial of carboplatin (C), paclitaxel (P), cetuximab (CX) and bevacizumab (B) followed by cetuximab and bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol. 2008; 3( suppl 4): S266. Abstract 9.
  • 46
    Bonomi P. A study of cetuximab and bevacizumab in combination with paclitaxel and carboplatin in stage IIIb/IV NSCLC. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00343291?term=bonomi&rank=1. Accessed March 10, 2009.
  • 47
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase 2 trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2004; 22: 2184-2191.
  • 48
    Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008; 14: 6317-6323.
  • 49
    Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non–small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008; 26: 3351-3357.
  • 50
    Zhu C-Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Clin Oncol. 2008; 26: 4268-4275.
  • 51
    Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372: 1809-1818.
  • 52
    Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5900-5909.
  • 53
    Mok TS, Leong S, Liu X, et al. Gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected chemonaive patients (pts) with advanced non-small-cell lung cancer (NSCLC) in Asia (IPASS): randomized, open-label, phase III study [abstract]. J Thorac Oncol. 2008; 3: S302.
  • 54
    Jackman DM, Sequist LV, Cioffredi L, et al. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8035.
  • 55
    Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26: 374-379.
  • 56
    De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19: 508-515.
  • 57
    Khambata-Ford S, Harbison C, Hart L, et al. K-Ras mutations (mt) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS099 study [abstract]. J Thor Oncol. 2008; 3( suppl 4): S304.
  • 58
    Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Ocol. 2007; 18: 977-984.
  • 59
    Fidias P, Dakhil S, Lyss A, et al. Phase 3 study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival [abstract]. J Clin Oncol. 2007; 25( 18S). Abstract LBA7516.
  • 60
    Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 8011.